Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Closing Price
$41.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
504,619

10-day average volume:
611,670
504,619

TherapeuticsMD Inc. Stock Falls Wednesday, Underperforms Market

5:25 pm ET September 7, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of TherapeuticsMD Inc. (TXMD) slumped 0.12% to $8.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.14% to 11,791.90 and the Dow Jones Industrial Average rising 1.40% to 31,581.28. This was the stock's second consecutive day of losses. TherapeuticsMD Inc. closed $32.81 short of its 52-week high ($40.90), which the company reached on October 21st.

The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 0.55% to $164.07, Merck & Co. Inc. (MRK) rose 0.52% to $86.87, and Novartis AG ADR (NOVN.EB) rose 1.47% to $80.94. Trading volume (77,025) remained 622,724 below its 50-day average volume of 699,749.

Data source: Dow Jones Market Data, FactSet. Data compiled September 7, 2022.

	

(END) Dow Jones Newswires

September 07, 2022 17:25 ET (21:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.